Immunocore announces closing of $75.0 Million Series C round

• Funding follows positive Phase 3 trial interim analysis data for tebentafusp in patients with metastatic uveal melanoma

 

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 January 2021) Immunocore, a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today announced the completion of a $75.0 million Series C private financing round.